Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merit Medical (MMSI) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.81 per share a year ago.

Merit Medical (MMSI) Q2 Earnings and Revenues Beat Estimates

Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6% Constant currency revenue* up 6.6% Constant currency revenue, organic,* up 5.0% GAAP operating margin of 13.6%, compared to 9.0% in prior year period Non-GAAP operating margin* of 20.1%, compared to 19.1% in prior year period GAAP EPS $0.61, up 75.7% Non-GAAP EPS* $0.92, up 16.8% † Comparisons noted in the bullet points are calculated for the current quarter compared with the same prior year period unless otherwise specified. * The constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures.

Merit Medical Reports Second Quarter 2024 Results and Raises Full-Year Guidance

SOUTH JORDAN, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced plans to release findings from its WAVE study. A pivotal, international, multicenter trial, the WAVE study examines the safety and efficacy of Merit's WRAPSODY Cell-Impermeable Endoprosthesis for treatment of stenosis in the venous outflow circuit.

Merit Medical to Present 6-Month Outcomes from Randomized Arm of WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study at Two Upcoming Medical Meetings

Becton, Dickinson and Co.

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?

BDX vs. MMSI: Which Stock Should Value Investors Buy Now?

Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.

Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?

SOUTH JORDAN, Utah, July 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million. EndoGastric Solutions' EsophyX® Z+ device delivers a durable, minimally invasive non-pharmacological treatment option for patients suffering from GERD.

Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.®

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Merit Medical (MMSI) is a Strong Growth Stock

Merit Medical (MMSI) recalls certain products containing syringes made by a Chinese manufacturer, Jiangsu Shenli.

Merit Medical (MMSI) Recalls Syringes Made by Jiangsu Shenli

SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024.

Merit Medical Systems to Announce Second Quarter 2024 Results on August 1, 2024

Merit Medical has shown solid performance with revenue and EBITDA growth, but has only tracked the broader med-tech market higher as investors wait for more exciting drivers. The company's WRAPSODY endovascular stent graft has potential to exceed management's projections, and could be a practice-changing $100M+ product with good clinical data. Merit's December 2023 convertible debt offering was well in excess of corporate needs, which leads me to believe that M&A is back on the table.

Merit Medical: Undervalued With Multiple Growth Drivers In Play

The U.S. Food and Drug Administration said on Friday that Merit Medical Systems has initiated a recall for plastic syringes supplied by Jiangsu Shenli Medical Production.

Merit Medical recalling plastic syringes supplied by Jiangsu Shenli Medical, US FDA says

Here's Why Merit Medical (MMSI) is a Strong Momentum Stock

Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?

Merit Medical (MMSI) Up 5% Since Last Earnings Report: Can It Continue?

Merit Medical's (MMSI) latest offering is likely to create an efficient approach to inflation, thereby providing improved patient care.

Merit Medical's (MMSI) Latest Launch to Boost Patient Care

Versatile analog device offers fast inflation and ease of use, streamlining patient care Versatile analog device offers fast inflation and ease of use, streamlining patient care

Merit Medical Launches basixSKY™ Inflation Device

Experienced healthcare veteran brings a broad background spanning clinical, regulatory, operations, marketing, and business leadership to Merit's Board of Directors Experienced healthcare veteran brings a broad background spanning clinical, regulatory, operations, marketing, and business leadership to Merit's Board of Directors

Merit Medical Shareholders Elect Silvia M. Perez as New Director

Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports “Continued Growth Initiatives” Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr.

Merit Medical Executive Leadership Team Update

Merit Medical's (MMSI) latest additions to its embolotherapy portfolio are likely to improve the patient experience.

Merit Medical (MMSI) to Expand Product Suite Via New Launch

SOUTH JORDAN, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced US Food and Drug Administration (FDA) 510(k) clearance for its Siege Vascular Plug. Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.

Merit Medical Expands Embolics Portfolio with New Siege™ Vascular Plug and Bearing nsPVA Express™ Prefilled Syringe

Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.

Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman, and CEO Brian Lloyd - CLO and Corporate Secretary Joe Wright - CCO Raul Parra - CFO Conference Call Participants Craig Bijou - Bank of America Securities Jason Bednar - Piper Sandler Jason Bedford - Raymond James Steve Lichtman - Oppenheimer Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Mike Matson - Needham & Company John Young - Canaccord Operator Ladies and gentlemen, thank you for standing by. Welcome to the MMSI First Quarter 2024 Earnings Call.

Merit Medical Systems, Inc. (MMSI) Q1 2024 Earnings Call Transcript

The headline numbers for Merit Medical (MMSI) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News for Merit Medical Systems Stock (MMSI)